Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
McKinsey
Harvard Business School
Express Scripts
Moodys

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Argininosuccinate

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Argininosuccinate: Patents, clinical trial progress, indications

Argininosuccinate is an investigational drug.

There have been 4 clinical trials for Argininosuccinate. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Ischemia, Sarcoma, and Mesothelioma. The leading clinical trial sponsors are Polaris Group, University of Colorado, Denver, and Washington University School of Medicine.

There are three hundred and eighty-two US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Argininosuccinate
TitleSponsorPhase
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue SarcomaPolaris Pharmaceuticals, Inc.Phase 2
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue SarcomaWashington University School of MedicinePhase 2
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and CisplatinPolaris GroupPhase 2/Phase 3

See all Argininosuccinate clinical trials

Clinical Trial Summary for Argininosuccinate

Top disease conditions for Argininosuccinate
Top clinical trial sponsors for Argininosuccinate

See all Argininosuccinate clinical trials

US Patents for Argininosuccinate

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Argininosuccinate   See Pricing Methods of expressing products in mammalian cells INTREXON CEU, INC. (Blacksburg, VA)   See Pricing
Argininosuccinate   See Pricing Methods and compositions for multiplex PCR LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)   See Pricing
Argininosuccinate   See Pricing Peptides and peptide/active compound conjugates for renal targeting MERCK PATENT GMBH (Darmstadt, DE)   See Pricing
Argininosuccinate   See Pricing Compositions of engineered human arginases and methods for treating cancer AERase, Inc. (Austin, TX)   See Pricing
Argininosuccinate   See Pricing Methods and compositions for multiplex PCR Life Technologies Corporation (Carlsbad, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Argininosuccinate

Drugname Country Document Number Estimated Expiration Related US Patent
Argininosuccinate World Intellectual Property Organization (WIPO) 2012027533 2030-08-25   See Pricing
Argininosuccinate China 104053786 2031-04-28   See Pricing
Argininosuccinate China 106912197 2031-04-28   See Pricing
Argininosuccinate China 107002123 2031-04-28   See Pricing
Argininosuccinate European Patent Office 2702170 2031-04-28   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Boehringer Ingelheim
Mallinckrodt
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.